Bank of New York Mellon
CRNX icon

Bank of New York Mellon’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bank of New York Mellon’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Buy
393,688
+34,969
+10% +$1.3M ﹤0.01% 1818
2026
Q1 		$13M Sell
358,719
-46,291
-11% -$2.07M ﹤0.01% 1780
2025
Q4 		$18.9M Buy
405,010
+5,376
+1% +$239K ﹤0.01% 1573
2025
Q3 		$16.6M Buy
399,634
+53,706
+16% +$1.72M ﹤0.01% 1639
2025
Q2 		$9.95M Buy
345,928
+1,349
+0.4% +$41.7K ﹤0.01% 1908
2025
Q1 		$11.6M Sell
344,579
-186
-0.1% -$6.95K ﹤0.01% 1777
2024
Q4 		$17.6M Buy
344,765
+32,825
+11% +$1.84M ﹤0.01% 1642
2024
Q3 		$15.9M Sell
311,940
-74,510
-19% -$3.84M ﹤0.01% 1700
2024
Q2 		$17.3M Buy
386,450
+89,972
+30% +$4.15M ﹤0.01% 1663
2024
Q1 		$13.9M Sell
296,478
-33,101
-10% -$1.3M ﹤0.01% 1783
2023
Q4 		$11.7M Sell
329,579
-162,468
-33% -$4.98M ﹤0.01% 1897
2023
Q3 		$14.6M Buy
492,047
+28,629
+6% +$590K ﹤0.01% 1718
2023
Q2 		$8.35M Buy
463,418
+40,629
+10% +$810K ﹤0.01% 2035
2023
Q1 		$6.79M Buy
422,789
+71,030
+20% +$1.31M ﹤0.01% 2132
2022
Q4 		$6.44M Buy
351,759
+10,277
+3% +$181K ﹤0.01% 2187
2022
Q3 		$6.71M Buy
341,482
+10,237
+3% +$209K ﹤0.01% 2140
2022
Q2 		$6.18M Buy
331,245
+14,208
+4% +$284K ﹤0.01% 2207
2022
Q1 		$6.96M Sell
317,037
-5,469
-2% -$111K ﹤0.01% 2262
2021
Q4 		$9.16M Buy
322,506
+20,161
+7% +$497K ﹤0.01% 2147
2021
Q3 		$6.37M Buy
302,345
+10,190
+3% +$213K ﹤0.01% 2371
2021
Q2 		$5.51M Buy
292,155
+5,578
+2% +$98K ﹤0.01% 2439
2021
Q1 		$4.38M Buy
286,577
+13,940
+5% +$216K ﹤0.01% 2498
2020
Q4 		$3.85M Buy
272,637
+95,325
+54% +$1.33M ﹤0.01% 2486
2020
Q3 		$2.78M Sell
177,312
-8,311
-4% -$127K ﹤0.01% 2492
2020
Q2 		$3.25M Buy
185,623
+149,591
+415% +$2.55M ﹤0.01% 2428
2020
Q1 		$529K Buy
36,032
+185
+0.5% +$3.79K ﹤0.01% 3331
2019
Q4 		$899K Buy
35,847
+1,183
+3% +$22.5K ﹤0.01% 3301
2019
Q3 		$521K Sell
34,664
-3,922
-10% -$76.3K ﹤0.01% 3514
2019
Q2 		$964K Buy
38,586
+12,608
+49% +$312K ﹤0.01% 3235
2019
Q1 		$591K Buy
25,978
+2,798
+12% +$68.8K ﹤0.01% 3472
2018
Q4 		$695K Buy
23,180
+7,367
+47% +$207K ﹤0.01% 3307
2018
Q3 		$453K Buy
+15,813
New +$469K ﹤0.01% 3690

Other funds holding CRNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $15.4B AUM 26.43% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return

Bank of New York Mellon's CRNX Position: Q2 2026 in Review

Bank of New York Mellon increased its Crinetics Pharmaceuticals (CRNX) stake by 9.7% in Q2 2026, buying an estimated $1.3M and bringing the position to 393,688 shares worth $14.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1818.

Bank of New York Mellon first reported a position in CRNX in Q3 2018 and has held it in 32 quarters since. The position peaked at $18.9M in Q4 2025. 124 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Bank of New York Mellon held 393,688 shares of Crinetics Pharmaceuticals worth $14.7M as of Q2 2026.
  • Bank of New York Mellon bought 34,969 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.3M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1818 holding.
  • Bank of New York Mellon first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
  • Bank of New York Mellon's Crinetics Pharmaceuticals position peaked at $18.9M in Q4 2025.
  • 124 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.